-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FhOkDdWEzLdDVs3eE1oSj2iYhUvBuyAdehqANNsdDs9pvla5mrTf9Gvejt7ybZwV NWUWs2Td9yultEpsgPRmRA== 0001236390-07-000003.txt : 20070731 0001236390-07-000003.hdr.sgml : 20070731 20070731210714 ACCESSION NUMBER: 0001236390-07-000003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070727 FILED AS OF DATE: 20070731 DATE AS OF CHANGE: 20070731 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENELABS TECHNOLOGIES INC /CA CENTRAL INDEX KEY: 0000874443 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943010150 STATE OF INCORPORATION: CA FISCAL YEAR END: 0107 BUSINESS ADDRESS: STREET 1: 505 PENOBSCOT DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 6503969500 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SMITH JAMES ANGUS DUNCAN CENTRAL INDEX KEY: 0001236390 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19222 FILM NUMBER: 071014103 BUSINESS ADDRESS: STREET 1: 423 CHESTNUT CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 6505621430 MAIL ADDRESS: STREET 1: 505 PENOBSCOT DR CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 primary_doc.xml PRIMARY DOCUMENT X0202 4 2007-07-27 0 0000874443 GENELABS TECHNOLOGIES INC /CA gnlb 0001236390 SMITH JAMES ANGUS DUNCAN 505 PENOBSCOT DR REDWOOD CITY CA 94063 0 1 0 0 President and CEO Incentive Stock Option Grant 1.96 2007-07-27 2007-07-27 4 A 0 33500 1.96 A 2017-07-27 commmon stock 33500 33500 D Incentive Stock Option Grant 1.96 2007-07-27 2007-07-27 4 A 0 76901 1.96 A 2017-07-27 Common Stock 76901 110401 D 25% of the shares are exercisable 6 moths from the grant date and the remainder vest prorata on a monthly basis over the following 36 month period. These options become 25% exercisable one year from grant date and the remainder prorata monthly over the next three years. James A.D. Smith 2007-07-31 -----END PRIVACY-ENHANCED MESSAGE-----